Onesource Specialty Pharma
- Market cap
- ₹ 15,216 Cr.
- P/E
- 688.2x
- P/B
- 2.71x
- 52-week range
- 1,057 – 1,925
- ROE
- −1%
- ROCE
- 1%
- Dividend yield
- 0%
- Debt / equity
- 0.26
- Sector
- Pharmaceuticals & Biotechnology
- Industry
- Pharmaceuticals
- Listed on
- NSE, BSE
About
OneSource Specialty Pharma Limited is an India-based vertically integrated biopharma service company with the capabilities to develop and manufacture complex biologics, biosimilars and vaccines. It operates as a specialty pharma pure-play contract development and manufacturing organization (CDMO). The Company specializes in prefilled syringes (with or without a safety device), dial and push variable and fixed dose pen injectors, pull push fixed dose pens and autoinjectors. Its integrated services offer comprehensive biologics solutions. It supports the development of complex biologics, including microbial and mammalian cell line biopharmaceuticals, cell and gene therapy and ribonucleic acid (RNA) products. The Company caters to a variety of capsule shapes and sizes, as well as formulations, traditional softgels to enteric coated capsules, vegan alternatives, chewable formats, vaginal pessaries, liposomal capsules, applicaps, and suppositories.
Quick check
The five things to look at first. Open one for more.
Compared with its industry
Pharmaceuticals: 221 companies →Onesource Specialty Pharma against the typical company in its industry. The rank is out of the companies that report each figure; green means the better quarter of the pack, red the worse quarter.
- Valuation (P/E)688.2 against a typical 33.2: pricier than most peers (1st = cheapest).218th of 220
- Sales growth+37.3% against a typical +15.6% from a year earlier.42nd of 197
- Share price, 3 months−9% against a typical −2%.133rd of 200
- Size₹ 15,215.9 Cr. market value against a typical ₹ 507.7 Cr. (1st = largest).32nd of 199
Latest announcements
Exchange filings and their impact on the company.
- Strong Q2 turnaround: revenue up 37% YoY with 5x PAT jump signals sustained profitable growth.
OneSource Specialty Pharma reported strong Q2 FY27 results with consolidated revenue of Rs 516.2 crore, up 37% from Rs 375.8 crore last year, and net profit of Rs 57.5 crore versus Rs 10.5 crore. For the first half, revenue was Rs 965.3 crore with net profit of Rs 82.5 crore, compared to a Rs 73.8 crore loss in full FY26. The growth with better margins and continued capex indicates the CDMO business has turned sustainably profitable.
Credit ratings
Every rating action on file, newest first, including reaffirmations. Open a row for the agency's reasoning. All credit rating updates
Adequate safety
Rated A by India Ratings- No warnings from the agency.
| Agency | Current rating | Outlook | As of |
|---|---|---|---|
| India Ratings | IND A; IND A1 | Positive | 17 Aug 2026 |
| CARE | Withdrawn | — | 5 Mar 2026 |
| Rating | Details | |||||
|---|---|---|---|---|---|---|
| 17 Aug 2026 | ▲ Upgrade1 notch | IND A- → IND A | — | India Ratings | ₹ 1,553.76 Cr. | |
| 5 Mar 2026 | Withdrawn | — | — | CARE | — | |
| 31 Dec 2025 | Reaffirmed | IND A- | — | India Ratings | ₹ 1,125.05 Cr. |
Board meetings
Results dates and other board meetings. Full calendar
| Details | ||
|---|---|---|
| 27 Oct 2026 | Financial Results | To consider and approve the financial results for the period ended September 30, 2026 |
| 24 Jul 2026 | Financial Results | To consider and approve the unaudited financial results for the period ended Jun 30, 2026 |
| 13 May 2026 | Financial Results | To consider and approve the financial results for the period ended March 31, 2026 |
| 23 Jan 2026 | Financial Results | To consider and approve the financial results for the period ended December 31, 2025 |
| 11 Nov 2025 | Financial Results | To consider and approve the financial results for the period ended September 30, 2025 |
| 4 Aug 2025 | Financial Results | To consider and approve the financial results for the period ended Jun 30, 2025 |
Financials
Consolidated figures in ₹ crore.
| ₹ Cr. | Sep 2023 | Dec 2023 | Mar 2024 | Jun 2024 | Sep 2024 | Dec 2024 | Mar 2025 | Jun 2025 | Sep 2025 | Dec 2025 | Mar 2026 | Jun 2026 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Sales | 34 | 56 | 73 | 292 | 334 | 393 | 426 | 327 | 376 | 290 | 428 | 449 |
| Expenses | 72 | 67 | 76 | 228 | 257 | 251 | 243 | 239 | 269 | 273 | 336 | 326 |
| Operating Profit | −39 | −10 | −3 | 64 | 77 | 142 | 183 | 88 | 106 | 17 | 92 | 123 |
| OPM % | −114% | −19% | −3.8% | 22% | 23% | 36% | 43% | 27% | 28% | 6% | 21% | 27% |
| Other Income | −32 | −74 | 3 | −1 | −1 | −94 | 2 | 2 | 3 | −2 | 2 | 0 |
| Interest | 25 | 26 | 20 | 42 | 45 | 46 | 33 | 27 | 34 | 38 | 23 | 31 |
| Depreciation | 18 | 20 | 20 | 68 | 68 | 69 | 68 | 68 | 70 | 70 | 72 | 72 |
| Profit before tax | −114 | −130 | −40 | −47 | −37 | −67 | 83 | −4 | 6 | −93 | 0 | 20 |
| Tax % | 0% | 0% | 0% | −88% | 12% | 4% | −19% | −96% | −83% | −5% | −1,630% | −23% |
| Net Profit | −114 | −130 | −40 | −6 | −42 | −69 | 98 | 0 | 10 | −89 | 5 | 25 |
| EPS in Rs | — | — | — | — | — | −6.02 | 8.61 | −0.02 | 0.92 | −7.74 | 0.4 | 2.18 |
Growth and returns
Compounded yearly rates over each period.
- 10 Years
- —
- 5 Years
- 131%
- 3 Years
- 232%
- TTM
- 4%
- 10 Years
- —
- 5 Years
- 8%
- 3 Years
- 24%
- TTM
- −142%
- 10 Years
- —
- 5 Years
- —
- 3 Years
- —
- TTM
- —
- 10 Years
- —
- 5 Years
- −10%
- 3 Years
- −2%
- TTM
- —
P/E and EPS over time
Daily P/E and trailing 12-month EPS. EPS updates with each result.
Peers
Listed companies in the same business.
| Onesource Specialty Pharma | ₹ 1,571.00 | ₹ 15,216 Cr. | 688.2x | 2.7x | −1% | — |
| Sun Pharmaceutical Industries | ₹ 1,743.00 | ₹ 4,18,194 Cr. | 38.4x | 5.6x | 14.2% | 19.1% |
| Divi's Laboratories | ₹ 8,984.00 | ₹ 2,38,497 Cr. | 73.3x | 11.5x | 16.2% | 24.3% |
| Torrent Pharmaceuticals | ₹ 4,482.00 | ₹ 1,70,475 Cr. | 72.7x | 19.2x | 27.1% | 15.3% |
| Cipla | ₹ 1,337.00 | ₹ 1,08,011 Cr. | 27.6x | 3.3x | 11.8% | 13.7% |
| Zydus Lifesciences | ₹ 1,127.85 | ₹ 1,12,503 Cr. | 21.2x | 4.2x | 19.7% | 18.5% |
Management
- Anurag Bhagania
- Chief Financial Officer
- Trisha Allada
- Company Secretary, Compliance Officer
- Neeraj Sharma
- Managing Director, Executive Director
Prices are delayed and for information only. Nothing on this page is investment advice.